Musli Thyropeutics Ltd.
🇮🇱Israel
- Country
- 🇮🇱Israel
- Ownership
- Private
- Established
- 2011-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.musli.co.il
Study of Induction of Hypothyroxinemia Adjunct to Conventional Therapies in GBM Patients
Phase 2
Terminated
- Conditions
- Glioblastoma Multiforme (GBM)
- Interventions
- Drug: Combined T3 and Methimazole treatment
- First Posted Date
- 2016-01-13
- Last Posted Date
- 2018-03-22
- Lead Sponsor
- Musli Thyropeutics Ltd.
- Target Recruit Count
- 3
- Registration Number
- NCT02654041
- Locations
- 🇮🇱
Tel-Aviv Medical Center, Israel, Tel-Aviv, Israel
© Copyright 2025. All Rights Reserved by MedPath